ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2048

Prognostic Value of Bronchoalveolar Lavage in CTD-related Interstitial Lung Disease: An Observational Study

Maximilian Gysan1, Svitlana Pochepnia2, Helmut Prosch2, Antje Lehmann1, Silvia Lee1, Andreas Renner1, Daniela Gompelmann3, Marco Idzko1, Iris Aykara4, Karolina Anderle4, Peter Weber4, Hans Kiener4, Michael Bonelli4, Daniel Mrak4, Daniel Aletaha5, Helga Lechner-Radner4 and Kastriot Kastrati4, 1Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 2Division of General and Paediatric Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 3Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria., Vienna, Austria, 4Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 5Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria

Meeting: ACR Convergence 2024

Keywords: Biomarkers, interstitial lung disease, longitudinal studies, prognostic factors, T-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The prognostic value of bronchoalveolar lavage (BAL) in connective tissue disease-related interstitial lung disease (CTD-ILD) is currently underexplored, resulting in a lack of understanding of disease progression and individual risk assessment in this population. Identifying patients with CTD-ILD, who are at risk of worsening disease presents a significant clinical challenge. Therefore, this study aims to examine the potential prognostic use of BAL in distinguishing between patients with progressive and non-progressive CTD-ILD.

Methods: Patients diagnosed with either newly onset or progressive CTD-ILD who underwent BAL were enrolled from rheumatology and pulmonology outpatient clinics. Standard-of-care assessments, including high-resolution computed tomography (HR-CT) and pulmonary function testing (PFT), were conducted at baseline and follow-up visits. The proportion of different cell types present in BAL fluid (BALF) was quantified. The demographic and clinical characteristics of these patients were comprehensively assessed, including age, gender distribution, disease duration, smoking history, extent of lung disease, and treatment modalities. Progression was defined using a composite outcome including the INBUILD criteria (a relative decline in forced vital capacity [FVC] ≥ 10%  OR a relative decline in FVC of ≥5% to £10% AND worsening of respiratory symptoms OR an increased extent of fibrosis on HR-CT OR worsening of respiratory symptoms and an increased extent of fibrosis), AND/OR necessity of lung transplantation AND/OR escalation of immunosuppressive therapy AND/OR death attributed to ILD. Multivariable logistic regression analysis was performed to identify risk factors of disease progression based on BALF cell types adjusting for patient and disease characteristics.

Results: We evaluated 100 patients diagnosed with CTD-ILD, encompassing various subtypes including myositis, systemic sclerosis, rheumatoid arthritis, mixed connective tissue disease, and Sjögren’s syndrome (Table 1). We identified 41 patients with progressive ILD. Ratio of Lymphocytes (%) in BALF was significantly increased in patients with progressive CTD-ILD (progressive: 28.8±22.8 vs. non-progressive: 14.3±16.5, p< 0.01). Multivariable logistic regression analysis demonstrated that the proportion of lymphocytes in BALF were an independent determinant of disease advancement (Odds Ratio: 1.05, 95% CI: 1.02-1.08, p=0.002), after adjusting for disease state at baseline (FVC, diffusing capacity of the lungs for carbon monoxide [DLCO]), HR-CT pattern of ILD, CTD diagnosis, and treatment regime (Table 2). Patients with >15% lymphocyte proportion in BALF showed significantly lower progression-free survival (Figure 1).

Conclusion: BALF analysis, particularly the proportion of lymphocytes, may serve as a valuable biomarker in CTD-ILD. It holds promise for individual risk stratification and guiding clinical decision-making in this patient population.

Supporting image 1

Table 1: Baseline characteristics of n=100 patients with connective tissue disease associated interstitial lung disease at time of bronchoalveolar lavage.

Supporting image 2

Table 2: Results of multivariable logistic regression analysis assessing the impact of various factors on disease progression in CTD-ILD. Odds ratios (OR) and corresponding 95% confidence intervals (CI) are reported for each predictor variable.

Supporting image 3

Figure 1: Kaplan-Meier curve showing the time to disease progression based on the proportion of lymphocytes in bronchoalveolar lavage (BAL) fluid. The curve compares two groups: patients with BAL lymphocyte proportion >15% (yellow) and those with BAL lymphocyte proportion ≤15% (blue). The group with lymphocyte levels >15% exhibits a significantly shorter time to progression (p=0.01).


Disclosures: M. Gysan: None; S. Pochepnia: None; H. Prosch: None; A. Lehmann: None; S. Lee: None; A. Renner: None; D. Gompelmann: None; M. Idzko: None; I. Aykara: None; K. Anderle: None; P. Weber: None; H. Kiener: None; M. Bonelli: None; D. Mrak: None; D. Aletaha: AbbVie, 2, 5, 6, Galapagos, 2, 5, 6, Gilead, 2, 5, 6, Janssen, 2, 5, 6, Lilly, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6; H. Lechner-Radner: None; K. Kastrati: None.

To cite this abstract in AMA style:

Gysan M, Pochepnia S, Prosch H, Lehmann A, Lee S, Renner A, Gompelmann D, Idzko M, Aykara I, Anderle K, Weber P, Kiener H, Bonelli M, Mrak D, Aletaha D, Lechner-Radner H, Kastrati K. Prognostic Value of Bronchoalveolar Lavage in CTD-related Interstitial Lung Disease: An Observational Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/prognostic-value-of-bronchoalveolar-lavage-in-ctd-related-interstitial-lung-disease-an-observational-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prognostic-value-of-bronchoalveolar-lavage-in-ctd-related-interstitial-lung-disease-an-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology